Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Clarissa C. Parker

AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Hernandez Cordero AI, Gonzales NM, Parker CC, Sokoloff G, Vandenbergh DJ, Cheng R, Abney M, Skol A, Douglas A, Palmer AA, Gregory JS, Lionikas A. Genome-wide Associations Reveal Human-Mouse Genetic Convergence and Modifiers of Myogenesis, CPNE1 and STC2. Am J Hum Genet. 2020 Jan 02; 106(1):138. PMID: 31901248.
      View in: PubMed
    2. Hernandez Cordero AI, Gonzales NM, Parker CC, Sokolof G, Vandenbergh DJ, Cheng R, Abney M, Sko A, Douglas A, Palmer AA, Gregory JS, Lionikas A. Genome-wide Associations Reveal Human-Mouse Genetic Convergence and Modifiers of Myogenesis, CPNE1 and STC2. Am J Hum Genet. 2019 12 05; 105(6):1222-1236. PMID: 31761296.
      View in: PubMed
    3. Yuan JT, Gatti DM, Philip VM, Kasparek S, Kreuzman AM, Mansky B, Sharif K, Taterra D, Taylor WM, Thomas M, Ward JO, Holmes A, Chesler EJ, Parker CC. Genome-wide association for testis weight in the diversity outbred mouse population. Mamm Genome. 2018 06; 29(5-6):310-324. PMID: 29691636.
      View in: PubMed
    4. Parker CC, Dickson PE, Philip VM, Thomas M, Chesler EJ. Systems Genetic Analysis in GeneNetwork.org. Curr Protoc Neurosci. 2017 Apr 10; 79:8.39.1-8.39.20. PMID: 28398643.
      View in: PubMed
    5. Parker CC, Gopalakrishnan S, Carbonetto P, Gonzales NM, Leung E, Park YJ, Aryee E, Davis J, Blizard DA, Ackert-Bicknell CL, Lionikas A, Pritchard JK, Palmer AA. Genome-wide association study of behavioral, physiological and gene expression traits in outbred CFW mice. Nat Genet. 2016 08; 48(8):919-26. PMID: 27376237.
      View in: PubMed
    6. Yazdani N, Parker CC, Shen Y, Reed ER, Guido MA, Kole LA, Kirkpatrick SL, Lim JE, Sokoloff G, Cheng R, Johnson WE, Palmer AA, Bryant CD. Hnrnph1 Is A Quantitative Trait Gene for Methamphetamine Sensitivity. PLoS Genet. 2015 Dec; 11(12):e1005713. PMID: 26658939.
      View in: PubMed
    7. Castro-Gomes V, Bergstrom HC, McGuire JL, Parker CC, Coyner J, Landeira-Fernandez J, Ursano RJ, Palmer AA, Johnson LR. A dendritic organization of lateral amygdala neurons in fear susceptible and resistant mice. Neurobiol Learn Mem. 2016 Jan; 127:64-71. PMID: 26642919.
      View in: PubMed
    8. Pallares LF, Carbonetto P, Gopalakrishnan S, Parker CC, Ackert-Bicknell CL, Palmer AA, Tautz D. Mapping of Craniofacial Traits in Outbred Mice Identifies Major Developmental Genes Involved in Shape Determination. PLoS Genet. 2015 Nov; 11(11):e1005607. PMID: 26523602.
      View in: PubMed
    9. Parker CC, Carbonetto P, Sokoloff G, Park YJ, Abney M, Palmer AA. High-resolution genetic mapping of complex traits from a combined analysis of F2 and advanced intercross mice. Genetics. 2014 Sep; 198(1):103-16. PMID: 25236452.
      View in: PubMed
    10. Carbonetto P, Cheng R, Gyekis JP, Parker CC, Blizard DA, Palmer AA, Lionikas A. Discovery and refinement of muscle weight QTLs in B6 × D2 advanced intercross mice. Physiol Genomics. 2014 Aug 15; 46(16):571-82. PMID: 24963006.
      View in: PubMed
    11. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433. PMID: 24722523.
      View in: PubMed
    12. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117. PMID: 24292963.
      View in: PubMed
    13. Cheng R, Parker CC, Abney M, Palmer AA. Practical considerations regarding the use of genotype and pedigree data to model relatedness in the context of genome-wide association studies. G3 (Bethesda). 2013 Oct 03; 3(10):1861-7. PMID: 23979941.
      View in: PubMed
    14. Fitzpatrick CJ, Gopalakrishnan S, Cogan ES, Yager LM, Meyer PJ, Lovic V, Saunders BT, Parker CC, Gonzales NM, Aryee E, Flagel SB, Palmer AA, Robinson TE, Morrow JD. Variation in the form of Pavlovian conditioned approach behavior among outbred male Sprague-Dawley rats from different vendors and colonies: sign-tracking vs. goal-tracking. PLoS One. 2013; 8(10):e75042. PMID: 24098363.
      View in: PubMed
    15. McGuire JL, Bergstrom HC, Parker CC, Le T, Morgan M, Tang H, Selwyn RG, Silva AC, Choi K, Ursano RJ, Palmer AA, Johnson LR. Traits of fear resistance and susceptibility in an advanced intercross line. Eur J Neurosci. 2013 Nov; 38(9):3314-24. PMID: 23968228.
      View in: PubMed
    16. Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33. PMID: 23893423.
      View in: PubMed
    17. Coyner J, McGuire JL, Parker CC, Ursano RJ, Palmer AA, Johnson LR. Mice selectively bred for High and Low fear behavior show differences in the number of pMAPK (p44/42 ERK) expressing neurons in lateral amygdala following Pavlovian fear conditioning. Neurobiol Learn Mem. 2014 Jul; 112:195-203. PMID: 23811025.
      View in: PubMed
    18. Parker CC, Chen H, Flagel SB, Geurts AM, Richards JB, Robinson TE, Solberg Woods LC, Palmer AA. Rats are the smart choice: Rationale for a renewed focus on rats in behavioral genetics. Neuropharmacology. 2014 Jan; 76 Pt B:250-8. PMID: 23791960.
      View in: PubMed
    19. Choi K, Le T, McGuire J, Xing G, Zhang L, Li H, Parker CC, Johnson LR, Ursano RJ. Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res. 2012 Jul; 46(7):882-9. PMID: 22534181.
      View in: PubMed
    20. Bartnikas TB, Parker CC, Cheng R, Campagna DR, Lim JE, Palmer AA, Fleming MD. QTLs for murine red blood cell parameters in LG/J and SM/J F(2) and advanced intercross lines. Mamm Genome. 2012 Jun; 23(5-6):356-66. PMID: 22322356.
      View in: PubMed
    21. Parker CC, Sokoloff G, Cheng R, Palmer AA. Genome-wide association for fear conditioning in an advanced intercross mouse line. Behav Genet. 2012 May; 42(3):437-48. PMID: 22237917.
      View in: PubMed
    22. Parker CC, Cheng R, Sokoloff G, Palmer AA. Genome-wide association for methamphetamine sensitivity in an advanced intercross mouse line. Genes Brain Behav. 2012 Feb; 11(1):52-61. PMID: 22032291.
      View in: PubMed
    23. Bryant CD, Parker CC, Zhou L, Olker C, Chandrasekaran RY, Wager TT, Bolivar VJ, Loudon AS, Vitaterna MH, Turek FW, Palmer AA. Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids. Neuropsychopharmacology. 2012 Mar; 37(4):1026-35. PMID: 22089318.
      View in: PubMed
    24. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      View in: PubMed
    25. Parker CC, Cheng R, Sokoloff G, Lim JE, Skol AD, Abney M, Palmer AA. Fine-mapping alleles for body weight in LG/J × SM/J F2 and F(34) advanced intercross lines. Mamm Genome. 2011 Oct; 22(9-10):563-71. PMID: 21761260.
      View in: PubMed
    26. Parker CC, Palmer AA. Dark matter: are mice the solution to missing heritability? Front Genet. 2011; 2:32. PMID: 22303328.
      View in: PubMed
    27. Sokoloff G, Parker CC, Lim JE, Palmer AA. Anxiety and fear in a cross of C57BL/6J and DBA/2J mice: mapping overlapping and independent QTL for related traits. Genes Brain Behav. 2011 Jul; 10(5):604-14. PMID: 21554534.
      View in: PubMed
    28. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83. PMID: 21421117.
      View in: PubMed
    29. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11. PMID: 21603121.
      View in: PubMed
    30. Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94. PMID: 21337123.
      View in: PubMed
    31. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R. Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47). PMID: 21304468.
      View in: PubMed
    32. Roy HK, Hensing T, Backman V. Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. Future Oncol. 2011 Jan; 7(1):1-3. PMID: 21174531.
      View in: PubMed
    33. Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010 Oct 15; 70(20):7748-54. PMID: 20924114.
      View in: PubMed
    34. Stinchcombe TE, Bradford DS, Hensing TA, LaRocca RV, Saleh M, Evans T, Bakri K, Socinski MA. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15. PMID: 19916742.
      View in: PubMed
    35. Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53. PMID: 20007525.
      View in: PubMed
    36. Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J, Chang JS, Backman V. Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res. 2009 Jul 01; 69(13):5357-63. PMID: 19549915.
      View in: PubMed
    37. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9. PMID: 19433684.
      View in: PubMed
    38. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008 Feb; 3(2):125-9. PMID: 18303431.
      View in: PubMed
    39. Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51. PMID: 18303435.
      View in: PubMed
    40. Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8. PMID: 18282359.
      View in: PubMed
    41. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53. PMID: 17805063.
      View in: PubMed
    42. Davis K, Yount S, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton D, Masters G, Hensing T, Cella D. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7. PMID: 17944147.
      View in: PubMed
    43. Cella D, Wagner L, Cashy J, Hensing TA, Yount S, Lilenbaum RC. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr. 2007; (37):53-60. PMID: 17951232.
      View in: PubMed
    44. Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704. PMID: 16917215.
      View in: PubMed
    45. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7. PMID: 16797779.
      View in: PubMed
    46. Bennett B, Downing C, Parker C, Johnson TE. Mouse genetic models in alcohol research. Trends Genet. 2006 Jul; 22(7):367-74. PMID: 16730093.
      View in: PubMed
    47. Hoang T, Kim K, Merchant J, Traynor AM, McGovern J, Oettel KR, Sanchez FA, Ahuja HG, Hensing TA, Larson M, Schiller JH. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25. PMID: 17409860.
      View in: PubMed
    48. Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60. PMID: 17409827.
      View in: PubMed
    49. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9. PMID: 16249215.
      View in: PubMed
    50. Hensing TA. Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):219-35, v. PMID: 15833404.
      View in: PubMed
    51. Gillenwater HH, Stinchcombe TE, Qaqish BF, Tyann M, Hensing TA, Socinski MA. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9. PMID: 15713525.
      View in: PubMed
    52. Hensing TA, Schell MJ, Lee JH, Socinski MA. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9. PMID: 15639724.
      View in: PubMed
    53. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004 Dec 01; 22(23):4837-45. PMID: 15570087.
      View in: PubMed
    54. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 01; 22(21):4341-50. PMID: 15514375.
      View in: PubMed
    55. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004 Oct; 11(10):900-6. PMID: 15383424.
      View in: PubMed
    56. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88. PMID: 12910523.
      View in: PubMed
    57. Socinski MA, Baggstrom MQ, Hensing TA. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8. PMID: 16227958.
      View in: PubMed
    58. Kwock L, Smith JK, Castillo M, Ewend MG, Cush S, Hensing T, Varia M, Morris D, Bouldin TW. Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat. 2002 Feb; 1(1):17-28. PMID: 12614173.
      View in: PubMed
    59. Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47. PMID: 12057099.
      View in: PubMed
    60. Hensing TA, Detterbeck F, Socinski MA. The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control. 2000 Jan-Feb; 7(1):45-55. PMID: 10740660.
      View in: PubMed
    61. Hensing TA, Socinski MA. Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med. 1999 Jul; 5(4):194-200. PMID: 10407686.
      View in: PubMed
    Parker's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Physical Neighbors Expand Description
    _